Abstract:Interactions between pro- and anti-apoptotic Bcl-2 proteins decide the fate of the cell. The BH3 domain of pro-apoptotic Bcl-2 proteins interacts with the exposed hydrophobic groove of their anti-apoptotic counterparts. Through their design and development, BH3 mimetics that target the hydrophobic groove of specific anti-apoptotic Bcl-2 proteins have the potential to become anticancer drugs. We have developed a novel computational method for designing sequences with BH3 domain features that can bind specifically to anti-apoptotic Mcl-1 or Bcl-XL. In this method, we retained the four highly conserved hydrophobic and aspartic residues of wild-type BH3 sequences and randomly substituted all other positions to generate a large number of BH3-like sequences. We modeled 20000 complex structures with Mcl-1 or Bcl-XL using the BH3-like sequences derived from five wild-type pro-apoptotic BH3 peptides. Peptide-protein interaction energies calculated from these models for each set of BH3-like sequences resulted in negatively skewed extreme value distributions. The selected BH3-like sequences from the extreme negative tail regions have highly favorable interaction energies with Mcl-1 or Bcl-XL. They are enriched in acidic and basic residues when they bind to Mcl-1 and Bcl-XL, respectively. With the charged residues often away from the binding interface, the overall electric field generated by the charged residues results in strong long-range electrostatic interaction energies between the peptide and the protein giving rise to high specificity. Cell viability studies of representative BH3-like peptides further validated the predicted specificity. This study has revealed the importance of non-hot spot residues in BH3-mimetic peptides in providing specificity to a particular anti-apoptotic protein.

An In-Tether Chiral Center Modulates the Proapoptotic Activity of the KLA Peptide.

Tumor-penetrating Peptide Fused to a Pro-Apoptotic Peptide Facilitates Effective Gastric Cancer Therapy

A Conserved Hydrophobic Core At Bcl-X(L) Mediates Its Structural Stability And Binding Affinity With Bh3-Domain Peptide Of Pro-Apoptotic Protein

Smart pH-Sensitive Nanogels for Enhancing Synergistic Anticancer Effects of Integrin αvβ3 Specific Apoptotic Peptide and Therapeutic Nitric Oxide

High yield purification of an Isoleucine zipper modified CD95 Ligand with either biotin or DNA-oligomer binding domain for efficient Cell Apoptosis Induction

Delivery of intracellular-acting biologics in pro-apoptotic therapies

Cell Permeable Bcl-2 Binding Peptides: A Chemical Approach to Apoptosis Induction in Tumor Cells

In-Tether Chiral Center Induced Helical Peptide Modulators Target P53-Mdm2/mdmx and Inhibit Tumor Growth in Stem-Like Cancer Cell

Novel X-linked Inhibitor of Apoptosis Protein Inhibitors As Probes of Apoptosis in Biology and Medicine

Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-XL: Role of Non-Hot Spot Residues

Structure-Based Discovery of an Organic Compound That Binds Bcl-2 Protein and Induces Apoptosis of Tumor Cells

Chemical Modification of Cytochrome C for Acid-Responsive Intracellular Apoptotic Protein Delivery for Cancer Eradication

Intrinsically Connected: Therapeutically Targeting the Cathepsin Proteases and the Bcl-2 Family of Protein Substrates as Co-regulators of Apoptosis

Synthesis and Helical Structure of Lactam Bridged BH3 Peptides Derived from Pro-Apoptotic Bcl-2 Family Proteins

A Novel Class of Peptides That Induce Apoptosis and Abrogate Tumorigenesisin Vivo

An In‐tether Chiral Center Modulates the Helicity, Cell Permeability, and Target Binding Affinity of a Peptide

A New Fusion Peptide Targeting Pancreatic Cancer and Inhibiting Tumor Growth.

Synthetic Peptide Sequence from the C-terminus of the Insulin-Like Growth Factor-I Receptor That Induces Apoptosis and Inhibition of Tumor Growth.

Biosynthesis of Multifunctional Transformable Peptides for Inducing Tumor Cell Apoptosis

Discovery of novel penetrating peptides able to target human leukemia and lymphoma for enhanced PROTAC delivery

Design, in silico evaluation, and in vitro verification of new bivalent Smac mimetics with pro-apoptotic activity